Amgen bispecific antibody therapy phase III Linchuan results announced reduce the risk of disease

Acute lymphocytic leukemia (B-ALL) is the most common leukemia in children. B-cell ALL makes children more susceptible to infection because cancerous B cells cannot perform their immune functions normally. Although existing therapies can cure most ALL patients, once the patient relapses, the prognosis drops rapidly, especially for high-risk ALL patients.

Amgen today announced that the results of a phase III clinical trial of the bispecific antibody therapy Blincyto 
(blinatumomab) for the first relapse of high-risk B-cell precursor acute lymphoblastic leukemia in children with 
acute lymphoblastic leukemia was published in (JAMA). Compared with consolidation chemotherapy, Blincyto 
can significantly prolong the event-free survival of patients (events include recurrence, death, new tumors or 
failure to achieve complete remission). Blincyto is a bispecific T cell adaptor (BiTE) developed by Amgen. One 
end binds to the CD19 antigen expressed on the surface of B cells, and the other end recruits T cells to the 
vicinity of cancer cells to promote their killing of cancer cells. Blincyto has been approved by the FDA to treat 
patients with relapsed/refractory B-cell ALL. It has also received accelerated approval from the FDA. The treatment 
has entered the first or second complete remission, but minimal residual disease (MRD) is greater than 0.1% 
of B-cell ALL. patient.